Cargando…

Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy

OBJECTIVES: To analyse trajectories of retail pharmaceutical expenditures from 2010 to 2019 in Italy to investigate whether there was a switch from public to private expenditure, how the composition of private and public expenditure changed, and whether there are correlations with supply/demand vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenzi, Jacopo, Gianino, Maria Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905933/
https://www.ncbi.nlm.nih.gov/pubmed/35260457
http://dx.doi.org/10.1136/bmjopen-2021-055421
_version_ 1784665296409198592
author Lenzi, Jacopo
Gianino, Maria Michela
author_facet Lenzi, Jacopo
Gianino, Maria Michela
author_sort Lenzi, Jacopo
collection PubMed
description OBJECTIVES: To analyse trajectories of retail pharmaceutical expenditures from 2010 to 2019 in Italy to investigate whether there was a switch from public to private expenditure, how the composition of private and public expenditure changed, and whether there are correlations with supply/demand variables. Answering these questions is important to assure pharmaceutical care to all citizens in a public health system where expenditure containment is the issue of pharmaceutical policies. DESIGN AND SETTING: Time-trend analysis was carried out in the Italian National Health System (NHS), between 2010 and 2019. We considered the following: public pharmaceutical expenditure with/without direct distribution of drugs, copayments, household out-of-pocket payments for drugs reimbursable/non-reimbursable by the NHS, and for drugs without prescription requirement. Correlations were tested between expenditure items and relevant statistics (Gini coefficient, resident population demographics, ages and categories of physicians, and current expenditure on health). RESULTS: The switch feared between public and private pharmaceutical expenditures was not found: private expenditure increased (average annual per cent change 1.5%; 95% CI 0.3% to 2.6%), but public spending remained stable (–1.0%; 95% CI –3.0% to 1.1%). Single items of expenditure exhibited significant pattern changes over the study period. A switch from public expenditure without direct distribution of drugs (–3.9%) to expenditure with direct distribution was found (+8.4%). Unexpected increases in household out-of-pocket payments for drugs reimbursable by the NHS (+6.1%) and in copayments (+4.9%) were shown. No notable correlations were found. CONCLUSIONS: This study offers insights into Italian experience that can be applied to other contexts and the results provide policy-makers issues to reflect on. The findings suggest that policies of pharmaceutical-expenditure management may have multiple effects and unexpected combined effects over time that should be considered when they are designed, and suggest that health policies must be adopted with a systematic logic and a broad and unified vision.
format Online
Article
Text
id pubmed-8905933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89059332022-03-25 Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy Lenzi, Jacopo Gianino, Maria Michela BMJ Open Health Economics OBJECTIVES: To analyse trajectories of retail pharmaceutical expenditures from 2010 to 2019 in Italy to investigate whether there was a switch from public to private expenditure, how the composition of private and public expenditure changed, and whether there are correlations with supply/demand variables. Answering these questions is important to assure pharmaceutical care to all citizens in a public health system where expenditure containment is the issue of pharmaceutical policies. DESIGN AND SETTING: Time-trend analysis was carried out in the Italian National Health System (NHS), between 2010 and 2019. We considered the following: public pharmaceutical expenditure with/without direct distribution of drugs, copayments, household out-of-pocket payments for drugs reimbursable/non-reimbursable by the NHS, and for drugs without prescription requirement. Correlations were tested between expenditure items and relevant statistics (Gini coefficient, resident population demographics, ages and categories of physicians, and current expenditure on health). RESULTS: The switch feared between public and private pharmaceutical expenditures was not found: private expenditure increased (average annual per cent change 1.5%; 95% CI 0.3% to 2.6%), but public spending remained stable (–1.0%; 95% CI –3.0% to 1.1%). Single items of expenditure exhibited significant pattern changes over the study period. A switch from public expenditure without direct distribution of drugs (–3.9%) to expenditure with direct distribution was found (+8.4%). Unexpected increases in household out-of-pocket payments for drugs reimbursable by the NHS (+6.1%) and in copayments (+4.9%) were shown. No notable correlations were found. CONCLUSIONS: This study offers insights into Italian experience that can be applied to other contexts and the results provide policy-makers issues to reflect on. The findings suggest that policies of pharmaceutical-expenditure management may have multiple effects and unexpected combined effects over time that should be considered when they are designed, and suggest that health policies must be adopted with a systematic logic and a broad and unified vision. BMJ Publishing Group 2022-03-08 /pmc/articles/PMC8905933/ /pubmed/35260457 http://dx.doi.org/10.1136/bmjopen-2021-055421 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Lenzi, Jacopo
Gianino, Maria Michela
Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title_full Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title_fullStr Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title_full_unstemmed Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title_short Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy
title_sort switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in italy
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905933/
https://www.ncbi.nlm.nih.gov/pubmed/35260457
http://dx.doi.org/10.1136/bmjopen-2021-055421
work_keys_str_mv AT lenzijacopo switchfrompublictoprivateretailpharmaceuticalexpendituresevidencefromatimeseriesanalysisinitaly
AT gianinomariamichela switchfrompublictoprivateretailpharmaceuticalexpendituresevidencefromatimeseriesanalysisinitaly